Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 8/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FPR1 | P21462 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152226 | 0.93 | EPHX2 (0.40) | EPHX2THRBGAAFASNFPR1 | |
| SCHEMBL14152219 | 0.84 | EPHX2 (0.41) | EPHX2THRBGAAFASNFPR1 | |
| SCHEMBL2299736 | 0.84 | EPHX2 (0.41) | EPHX2THRBGAAFASNFPR1 | |
| SCHEMBL2299286 | 0.82 | KMT2A (0.48) | EPHX2THRBFPR1FPR2 | |
| SCHEMBL14152796 | 0.82 | KMT2A (0.48) | EPHX2THRBFPR1FPR2 | |
| SCHEMBL2295438 | 0.82 | KMT2A (0.48) | EPHX2THRBFPR1FPR2 | |
| SCHEMBL14152019 | 0.81 | EPHX2 (0.40) | EPHX2THRBGAAFASNFPR1 | |
| SCHEMBL14152164 | 0.81 | EPHX2 (0.40) | EPHX2THRBGAAFASNMAPT | |
| SCHEMBL14152248 | 0.80 | EPHX2 (0.39) | EPHX2THRBGAAFASNMAPT | |
| SCHEMBL2298365 | 0.79 | THRB (0.44) | EPHX2THRBGAAMAPTFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340529-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-8802864-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | EPHX2 2041/4885THRB 2070/4885GAA 1293/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | EPHX2 1852/4885THRB 1794/4885GAA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.